Article
Benefits of PDT more far-reaching than previously expected
Orlando-Photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Ophthalmics) is used widely to treat predominantly classic choroidal neovascularization (CNV) in age-related macular degeneration (AMD). The therapy, however, has met clinician resistance for treating occult CNV despite good visual results in the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study and the Verteporfin in Photodynamic Therapy (VIP) Trial, according to Joan W. Miller, MD.
Related Videos
Related Content
Published: December 19th 2024 | Updated: December 19th 2024
Study validates long-term efficacy of MicroPulse TLT for glaucoma management
